Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

Exploring the Role of Pharmacology in Personalized Medicine: From Bench to Bedside

Bhavani Ganapathy[1], Subbulakshmi Packirisamy[2], Valli Nachiyar C[3], Aarthi P[4], Yamuna V[5], Hari Hara Subramanyan P.V.[6]

[1]Department of Pharmacology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research.
[2]Department of Pharmacolgy, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research.
[3]Department of Research, Meenakshi Academy of Higher Education and Research
[4]Meenakshi College of Nursing, Meenakshi Academy of Higher Education and Research.
[5]Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research
[6]Associate Professor, Meenakshi College of Physiotherapy, Meenakshi Academy of Higher Education and Research

*Corresponding Author

Article History
Received: 12.07.2025
Revised: 23.08.2025
Accepted: 19.08.2025
Published: 27.09.2025

Abstract: ***Background:*** Pharmacology and the molecular medicine development has been altered so that the approach is taken to the healthcare, and it is no longer a general treatment advice but individual medicine. The paradigm tries to customize therapies based on genetic, environmental and lifestyle differences and increase the success and reduce adverse drug reactions. This shift revolves around pharmacology because it is what will guarantee the transfer of research in the laboratory bench to the patient bedside. ***Purpose:*** The aim of this paper is to talk about the role of pharmacology in personalized medicine and how pharmacogenomics, drug development, and translational research can assist in personalized care to the patients. ***Methods:*** The scientific literature of the period 20102023 was analysed by means of a narrative review in databases, such as PubMed, Scopus, and Web of Science. Articles have been selected that discussed the pharmacological innovations, personalized therapy based on genomics and clinical applications of individual therapeutic applications. Data synthesis was applied to give information about the trends and practical challenges in introducing precision medicine which is pharmacology driven. ***Results:*** The review revealed that pharmacogenomics has made a tremendous positive contribution in the selection and dosing of drugs particularly in the fields of oncology, psychiatry and cardiology. The discovery of biomarkers predictive of drug action has become possible with the innovation in the area of molecular pharmacology and this is utilized in designing targeted therapies. Translational pharmacology has also helped to close the communication gap between the laboratory and clinical practice hence accelerating the process of drug discovery. However, some problems remain, including the fact that the cost of genomic testing is still high, and it is not always available to patients, and that healthcare professionals have to educate themselves about pharmacogenomics. ***Conclusion:*** The evolution of personalized medicine is aimed at the pharmacology, which is expected to ensure that the treatment process is safe, effective, and patient-specific. Pharmacology enables the attainment of precise healthcare as the relationship between the clinical usage and the molecular discoveries. The additional investment in the study of pharmacogenomics, cross-disciplinary activities, and equality of opportunities will be the keys to the complete exploitation of the potentials of personalized medicine on bench to bedside.

Keywords: Drug response, pharmacogenomics, targeted therapy, pharmacology, precision healthcare.

INTRODUCTION

Modern medicine has been largely based on pharmacology, as the basis of discovery, development and clinical application of therapeutic agents. Traditionally, the treatment of drugs has been founded on the paradigm of a one-size-fits-all, that is, the drugs are prescribed based on the average of the populations but not the differences. However, the approach has a disposition of overlooking genetic variations, environmental exposures, and lifestyles that lead to an optimum response to treatment and adverse reaction to drugs [1]. Personalized medicine is a growing field that aims at addressing these issues by modifying medical practice to individual characteristics of individual patients to improve effectiveness and safety.

Pharmacogenomics is the pillar of personalized medicine, that is a branch of pharmacology, which examines how genetic variations interact with drug absorption, metabolism and reaction. The research studies have suggested that the polymorphisms in genes of CYP2D6, CYP2C19 and TPMT play a major role in the metabolism of commonly used drugs, such as antidepressants, antiplatelet drugs and chemotherapeutic drugs [2]. By implementing the pharmacogenomic testing into clinical practice, physicians can select the appropriate medications and dosage of those medications to individual patients to reduce the risks of therapeutic failure or adverse effects [3].

Translational

pharmacology as an intermediary between bench and bedside has simplified the incorporation of laboratory

results into clinical practice. Molecular pharmacology is used to find out the biomarkers of predicted drugs response in the preclinical field which in turn affect the clinical trials that should be applied in a given treatment. One case in point is the use of HER2 inhibitors such as trastuzumab in the treatment of breast cancer patients with the HER2 gene amplification. This is a model of therapeutics with precision modeled based on biomarkers that is explained in the form of pharmacology [4].

Besides oncology, other areas such as cardiology, psychiatry and infectious disease have also shown positive prospects of personalized pharmacology. Cardiology Pharmacogenomic testing of CYP2C19 variations is applied to choose antiplatelet therapy to be used following stent implantation, which increases patient outcomes [5]. Psychiatric testing of the cytochrome P450 enzymes through genetic testing helps in prediction of the antidepressant metabolism to shorten the drug trial and error period [6]. These are just some of the examples that show that pharmacological research directly affects the clinical decision-making in different areas.

Despite these advances, individualized pharmacology still has problems in terms of its popularity. Quality Genomic testing is costly to prohibitive levels, it is not available in low and middle income countries and the clinicians are not trained in pharmacogenomics [7]. Some ethical and regulatory concerns are also present like privacy of genetic information and equitable distribution of tailor-made therapies. Pharmacologists, geneticists clinicians and policymakers are required in order to break those barriers.

In summary, pharmacology is one of the most important aspects of the development and practice of personalized medicine that translates the knowledge of the molecular concepts into the therapy of the patient. In the case of a definition of genetic predictors of drug response to determine certain clinical interventions, pharmacology has contributed to bridging the gap between the research laboratory and the clinical setting. Along with the decrease in cost and increased access to technology, the integration of pharmacogenomics and translational pharmacology into routine care, is a healthcare delivery revolution that can be utilized.This paper discusses the emerging role of pharmacology in personalized medicine, which has been used throughout drug development, clinical practice, and issues that need to be overcome to achieve the potential.

2 Background work

The use of medicines is a safe and effective process that relies on the pharmacology which gives scientific foundation to the understanding of the drug actions, metabolism and the therapeutic uses. In the past, pharmacological studies were carried out to advance the creation of standard treatment programs to be used by most patients. Nonetheless, the effectiveness of this classic, one-size-fits-all model is not always sufficient to explain the fact that the range of drug response between different individuals is at times quite large. Research has estimated that as many as 50 percent of patients might not respond suitably to the widely prescribed drugs whereas adverse drug reactions are the major cause of morbidity and mortality in various parts of the world [8]. These prohibitions have led to the transition to personalized medicine which is an involvement method that tailors interventions to the separate genetic, to the environmental and to the lifestyle factors [2].

The basic element of personalized medicine is the pharmacogenomics, the science of the genetic variations in the drug responses. The occurrence of single nucleotide polymorphism (SNPs) in those genes that encode drug-metabolizing enzymes, drug transportation systems, and receptors impacts a lot on pharmacodynamics and pharmacokinetics. An example is the metabolism of antidepressants and analgesics which is influenced by the CYP2D6 gene variation, and the mutation in the TPMT gene predicts the severe response to thiopurine drugs [2]. Pharmacology is advantageous in that it provides practical data, which is more useful in selecting drugs, dosage and toxicity [3]. Translational pharmacology facilitates the translation of laboratory basic findings to clinical practice. The latest achievements in molecular biology and bioinformatics assist scientists in identifying biomarkers that are likely to forecast therapeutic response. These types of biomarkers have been used in targeted therapies with particular use in oncology.

The example of trastuzumab in the treatment of HER2-positive breast cancer and imatinib in the treatment of chronic myeloid leukemia shows how pharmacological inventions can be developed to travel between the bench and the bedside and change the treatment of patients [4].

Although it has been promised to make progress, there are still issues in applying personalized pharmacology into clinical practice. The challenges involve the prohibitive nature of genomic testing, inequality in patient access and insufficiency in training medical practitioners in pharmacogenomics [6]. Ethical issues, including privacy of genetic data and fairness in the provision of precision therapies are also to be addressed [7]. Meeting these issues requires an integrated action among the pharmacologists, clinicians, policymakers and educators, so that there is equal implementation of the personalized medicine approaches.

To conclude, pharmacology is the foundation of personalized medicine, and it is possible to bring the findings of molecular knowledge to individual therapy. It is possible to combine pharmacogenomics with translational pharmacology and change the general

approach to treatment with precision strategies that would improve safety, efficacy, and patient-centered outcomes in healthcare [9].

Graphical Abstract



MATERIALS AND METHODS

Study Design

The study was established as a narrative review with the aim of summarizing the existing research on the application of pharmacology in personalized medicine. The choice of the narrative review approach was to enable the in-depth investigation of the pharmacogenomics, translational pharmacology, and clinical implementation, which connects evidence of laboratory studies to the clinical practice.



Fig.2. Key stages involved in translating pharmacological research

It is seen that as illustrated in the figure 2 that the main steps that each research translates pharmacology to individual patient care include the following essential steps. It focuses on the scientific finding axes to clinical application spectrum.

Data Sources

The literature was also gathered in the electronic databases such as PubMed, Scopus, Web of Science, and ScienceDirect. Other gray literature was also found using Google scholar and the websites of the official organizations, including the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Screening of reference lists of the key articles was also done to obtain the additional relevant studies.

Search Strategy

The structured search strategy was created on the basis of Medical Subject Headings (MeSH) and the free-text keywords. The keywords used with Boolean operators were used in various combinations as follows:

1.Pharmacology or Pharmacogenomics or Translational pharmacology.
2. Personalized medicine OR Precision medicine.
3.Drug response or Biomarkers or the Targeted therapy
4.Bench to bedside OR Clinical application.

Articles published since 2010 and up to the year 2023 were restricted, so the latest developments in the field of pharmacology and personalized medicine could be considered.

Inclusion and Exclusion Criterion.

Inclusion criteria:

Articles published in peer-reviewed journals that concentrate on the topic of pharmacogenomics, personalized medicine, and translational pharmacology.

Clinical trials, meta-analyses, systematic reviews and observational studies. The research studies that involve human subjects or are based on pharmacological models that are clinically relevant.

Exclusion criteria:

Articles published before 2010. Research not based on pharmacology or drug treatment. Publications in other languages other than English. Abstract without adequate methodological description Case reports or conference abstracts.

Data Extraction

Titles and abstracts were screened as per relevancy by two reviewers. Articles containing full-text were obtained and subjected to detailed analysis as per the eligibility requirements. Data extraction focused on:

1.Study design and setting,

2.Pharmacological emphasis (e.g. drug metabolism, pharmacogenomics, biomarker identification),

3.Personalized medicine, and clinical uses of pharmacology.

4.Problems and future trends reported.

Data Synthesis

Information retrieved was summarized as a story to bring out the trends in the use of pharmacology in informing personalized medicine. The results were summarized into three themes:

1.Pharmacogenomics Pharmacogenomic predictors of drug response and clinical uses.

2.Translational Pharmacology -coordination of biomarker studies and laboratory findings in clinical trials and therapy.

3.Clinical Implementation- bedside practice, issues, and policy implications.

It was also found that the synthesis process also revealed gaps in the literature, especially in the aspects of cost-effectiveness, accessibility and ethical considerations of personalized pharmacology.

Ethical Considerations

Since this was a literature-basedresearch, where secondary data has been used, no human or animal subjects were dealt with. It was not therefore necessary to seek ethical approval. Nevertheless, all sources of data were referenced appropriately to prevent a lack of academic integrity and the plagiarism problem.

RESULTS AND OBSERVATIONS:

The literature review presented that pharmacology, specifically, pharmacogenomics, biomarker discovery, and translational pharmacology are the key elements in the development of personalized medicine. In various fields of therapy, facts show that pharmacology-based interventions enhance treatment effectiveness, reduce adverse drug reactions and enhance cost effective healthcare provision.

Table 1. Pharmacological Contributions to Personalized Medicine Across Clinical Areas

Clinical Area	Pharmacological Contribution	Example Application	Outcomes Reported
Oncology	Biomarker-driven targeted therapy	HER2 inhibitors (trastuzumab) in breast cancer	Improved survival; reduced relapse [4]
Cardiology	Pharmacogenomic-guided antiplatelet therapy	CYP2C19 genotyping for clopidogrel	Lower risk of stent thrombosis [5]
Psychiatry	Cytochrome P450 genetic testing for antidepressants	CYP2D6/CYP2C19 testing in SSRI metabolism	Faster treatment response; fewer adverse effects [12]
Infectious Disease	Pharmacodynamics in antimicrobial stewardship	PK/PD modeling for antibiotic dosing	Reduced resistance; optimized dosing [4]
Pain Management	Opioid receptor polymorphism and metabolism	OPRM1 and CYP2D6 variants in analgesic response	Tailored opioid therapy; lower risk of misuse [11]

DISCUSSION

A Cradle of Individualization: Pharmacogenomics.

The key point that emerges as one of the most robust findings of the reviewed literature is the crucial position of pharmacogenomics in the directive individualized therapy. Drug response interpatient variations are greatly attributed to

variations in the enzymes, transporters and receptors that metabolize drugs. An example is the CYP2C19 genotyping, which is currently a standard step in the cardiology-guided clopidogrel therapy to assure effective platelet inhibition [5]. Other uses of biomarker therapies have also demonstrated remarkable gains in oncology, including the use of HER2 testing in breast cancer to guide the usage of trastuzumab [4].



Fig.3. Role of pharmacology in personalized medicine

Translational Pharmacology Bridging Bench to Bedside

The discovery of molecular pharmacology, as well as the discovery of biomarkers, has hastened the application of laboratory discoveries to the clinic. Translational pharmacology helps to develop a specific therapy intended to address a disease between drug discovery and clinical practice. Imatinib used on chronic myeloid leukemia and immune checkpoint inhibitors used in oncology are examples that came about as a result of preclinical pharmacological understanding [6].



Fig.4. Bench to beside pathway

Psychiatry and Pain Management

Psychiatric pharmacology demonstrates that the pharmacogenetic testing is useful in reducing the trial and error stage of the antidepressant treatment. Hicks et al. [12] found out that, clinical response and lesser side effects were enhanced in case antidepressant dosing was readjusted based on CYP450 genotyping. In their introduction of the safe opioid prescribing models, genetic differences in opioid metabolism (CYP2D6) and opioid receptor sensitivity (OPRM1) are being incorporated, which would decrease the risk of misuse and adverse outcomes [11].

Unfavorable Implementation Issues.

Regardless of the strong arguments, the personalization through pharmacology has a number of barriers to its extensive clinical implementation. The affordability and cost of pharmacogenomic test is also a significant concern particularly in the low and the middleincome countries. In addition, lack of consistency in knowledge and training of clinicians limits the use of pharmacogenomics in the practice [7]. The privacy of genetic data is also the issue of ethical and legal concern as the number of those who are using electronic health records increases.

Policy and the Future directions.

Multi-level intervention is required to resolve the hindrances that these problems require. This will be added to through investment in cost saving genomic technologies, introduction of pharmacogenomics into medical education and the development of explicit clinical guidelines. The global health structures should also avoid warped disparities in health [1] which will offer equitable access to personalized medicine which is becoming more pharmacological in nature.

Summary of Discussion

It has been discussed that pharmacology is a key to personalized medicine since it connects the molecular to the clinical discovery in every field of oncology, cardiology, psychiatry, infectious diseases and pain management. Despite the existing challenges, personalized pharmacology has emerged as one of the highest research, policy, and clinical practice agendas because of the ability to transform the face of healthcare by offering safer, more effective, and patient-specific treatments.

CONCLUSION

While not all associations reached statistical Pharmacology as a field of study takes a central role in the field of development of personalized medicine since it constitutes the interface between laboratory discoveries and clinical practice. All this has been transformed through pharmacogenomics, molecular pharmacology and translational research where one can no longer afford to generalize and administer drugs to people but they can now afford to individualize the therapy in accordance with the genetic profile, environment and the lifestyle of an individual. The evidence of oncology, cardiology, psychiatry, infectious disease, and pain management shows that interventions based on pharmacology could be adopted to enhance the effect of drugs, reduce side effects, and enhance patient outcomes in general. The translation of pharmacological knowledge to bedside practice has already produced the breakthrough therapies of targeted cancer drugs and genotype directed cardiovascular and psychiatric therapies. However, issues of large-scale clinical adoption still exist including the cost of genetic testing is prohibitive, not every individual can access precision medicine, the majority of clinicians are not trained yet, and the privacy of genetic information is a somewhat debatable ethical issue. Such barriers demand a long-term partnership between the researchers and the systems of health service delivery and the policy makers and the educational institutions. Finally, personalized medicine will be attained on the basis of pharmacology science and practice. The healthcare systems will be in a position to provide safer, more effective and patient-centered treatments by adopting the advancement of pharmacogenomic and investing in the research of the trans-theoretical and rendering such treatments affordable to all members of the society. The pharmacology would have to be developed further so that the concept of precision medicine becomes a groundbreaking one that would become a standard across every part of the world.

REFERENCES

1. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.
2. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103–141.
3. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343–350.
4. Slamon, D. J., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer. New England Journal of Medicine, 344(11), 783–792.
5. Mega, J. L., et al. (2010). Cytochrome P-450 polymorphisms and response to clopidogrel. New England Journal of Medicine, 360(4), 354–362.
6. Hicks, J. K., et al. (2015). Clinical pharmacogenetics implementation consortium guidelines for CYP2D6 and CYP2C19 genotypes and antidepressant dosing. Clinical Pharmacology & Therapeutics, 98(2), 127–134.
7. Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., & Peterson, J. F. (2019). Pharmacogenomics: The genetics of variable drug responses. Circulation, 140(12), 869–877.
8. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients. JAMA, 279(15), 1200–1205.
9. Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301–304.
10. Roberts, J. A., & Lipman, J. (2009). Pharmacokinetic issues for antibiotics in critically ill patients. Critical Care Medicine, 37(3), 840–851.

11. Mura, E., et al. (2013). OPRM1 and CYP2D6 polymorphisms in opioid response. Pain Physician, 16(6), E685–E700
12. Druker, B. J., et al. (2001). Efficacy of imatinib in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031–1037